Abstracts tagged "longitudinal studies"

Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…
Abstract Number: 0853 • ACR Convergence 2021
A Combined Patient Registry and Biobank Laboratory Information System for Prospective Multisite Chronic Rheumatic Disease Research Using REDCap
Craig Willers¹, Tom Lynch¹, Vibhasha Chand², Mohammad Islam³, Marissa Lassere⁴, Helen Keen⁵, Tony Kenna⁶, Susan Lester⁷, Ranjeny Thomas⁸, Premarani Sinnathurai⁹, Mihir Wechalekar¹⁰, Ashley Fletcher¹¹, Daniel Lightowler¹², Sheeraz Mohd¹³, Nishta Ramnoruth¹⁴, Carlee Ruediger¹⁵, Helen Weedon¹⁶ and Lyn March¹⁷, ¹Institute of Bone and Joint Research, Kolling Institute, University of Sydney, St Leonards, Australia, ²Public Health and Preventive Medicine, Monash University, Melbourne, Australia, ³Information and Communications Technology, University of Sydney, Sydney, Australia, ⁴St George Hospital; School of Population Health, University of New South Wales, Carlton, Australia, ⁵University of Western Australia, Daglish, Australia, ⁶Queensland University of Technology, School of Biomedical Sciences, Brisbane, Australia, ⁷Rheumatology Department, The Basil Hetzel Institute, The Queen Elizabeth Hospital, Adelaide, Australia, ⁸University of Queensland, Diamantina Institute, Brisbane, Australia, ⁹Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, Sydney, Australia, ¹⁰Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, ¹¹Cabrini Health, Malvern, Australia, ¹²Medical School, University of Western Australia; Rheumatology Department, Fiona Stanley Hospital, Perth, Australia, ¹³Fiona Stanley Hospital, South Metropolitan Health Services, Perth, Australia, ¹⁴Diamantina Institute, University of Queensland, Brisbane, Australia, ¹⁵University of Adelaide; The Queen Elizabeth Hospital, Adelaide, Australia, ¹⁶Flinders University, Bedford Park, Australia, ¹⁷Institute of Bone and Joint Research, Kolling Institute, University of Sydney; Department of Rheumatology, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, Sydney, Australia
Background/Purpose: As we enter the big data revolution, comprehensive informatics solutions are essential to realising precision medicine for rheumatic and other chronic disease patients, especially…
Abstract Number: 0897 • ACR Convergence 2021
Age-Stratified Trend of Spinal Radiographic Damage Progression in Patients with Ankylosing Spondylitis
Tae-Han Lee¹, Bon San Koo², Bora Nam³, Seunghun Lee⁴, Kyung Bin Joo⁴ and Tae-Hwan Kim³, ¹Keimyung University Dongsan Hospital, Daegu, Republic of Korea, ²Inje University Seoul Paik Hospital, Seoul, Republic of Korea, ³Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁴Hanyang University Hospital, Seoul, Republic of Korea
Background/Purpose: Previous studies investigating the course of spinal structural progression in patients with ankylosing spondylitis (AS) using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS)…
Abstract Number: 0932 • ACR Convergence 2021
Sequential Treatment in Axial Spondyloarthritis – Real World Data from a Network of German Rheumatologists
Stefan Kleinert¹, Peter Bartz-Bazzanella², Cay Von der Decken³, Kirsten Karberg⁴, Florian Schuch⁵, Georg Gauler⁶, Patrick Wurth⁷, Susanna Späthling-Mestekemper⁸, Christoph Kuhn⁹, Fabian Proft¹⁰, Denis Poddubnyy¹¹, Mathias Englbrecht¹² and Wolfgang Vorbrüggen¹³, ¹Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany, ²Rhein-Maas Klinikum, Wuerselen, Germany, ³Klinik für Internistische Rheumatologie, Rhein-Maas-Klinikum, Würselen, Germany, ⁴Praxis für Rheumatologie und Innere Medizin, Berlin, Germany, Berlin, Germany, ⁵Praxisgemeinschaft Rheumatologie-Nephrologie, Erlangen, Germany, ⁶rheumapraxis, Osnabrck, Germany, ⁷Rheumatologische Schwerpunktpraxis, Osnabrück, Germany, ⁸Rheumapraxis München, München, Germany, ⁹Praxis für Rheumatologie, Karlsruhe, Germany, Karlsruhe, Germany, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ¹²Freelance Healthcare Data Scientist, Eckental, Germany., Eckental, Germany, ¹³Verein zur Förderung der Rheumatologie e.V., Würselen, Germany
Background/Purpose: Increasing immunmodulatory treatment options are available for axial spondyloarthritis. Little is known about sequential treatment in clinical routine.Methods: The pseudonymized RHADAR database (Kleinert, S.…
Abstract Number: 1158 • ACR Convergence 2021
Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Kaleb Michaud¹, Sofia Pedro², Victoria Jasion³, Holly Budlong⁴, Jessica Suboticki⁵, Frederick Wolfe⁶ and Patricia Katz⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³AbbVie, Overland Park, KS, ⁴AbbVie, Minneapolis, MN, ⁵AbbVie Inc., North Chicago, IL, ⁶National Data Bank for Rheumatic Diseases, Wichita, KS, ⁷University of California San Francisco, San Francisco, CA
Background/Purpose: Treatment options for rheumatoid arthritis (RA) have increased dramatically over the past 15 years. The objective of this study was to investigate whether willingness…
Abstract Number: 1197 • ACR Convergence 2021
Periodontal Status Before Diagnosis in Patients with Rheumatoid Arthritis Predicts Cumulative Disease Activity in Years After Treatment Inititation
Adelina Plachokova¹, Jill Hadisurya¹, Julia van Bergen² and Rogier Thurlings³, ¹Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, Netherlands, ²Radboudumc, department of Dentistry (Implantology & Periodontology), Nijmegen, ³Radboud University Medical Centre, Nijmegen, Netherlands
Background/Purpose: Transversal cohort studies demonstrated a possible association between periodontal disease (PD) and rheumatoid arthritis (RA). However it is unknown how this association evolves during…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
Abstract Number: 1220 • ACR Convergence 2021
Identification of Underlying Disease Domains by Longitudinal Latent Factor Analysis for Secukinumab Treated Patients in Psoriatic Arthritis and Rheumatoid Arthritis Trials
Xuan Zhu¹, Fabian Falck², Sahra Ghalebikesabi², Matthias Kormaksson¹, Marc Vandemeulebroecke³, Cong Zhang¹, Luis Santos⁴, Chun Hei Kwok⁴, Dominique West⁴, Ann-Marie Mallon⁴, Ruvie Martin¹, Aimee Readie¹, Kunal Gandhi¹, Gregory Ligozio¹ and George Nicholson², ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²University of Oxford, Oxford, United Kingdom, ³Novartis Pharma AG, Basel, Switzerland, ⁴MRC Harwell Institute, Harwell Campus, Oxfordshire, United Kingdom
Background/Purpose: Secukinumab is a fully monoclonal antibody approved for the treatment of several related autoinflammatory diseases, including psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis.1 While…
Abstract Number: 0159 • ACR Convergence 2021
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Xenofon Baraliakos¹, Valeria Rios Rodriguez², Murat Torgutalp², Anil Dilbaryan², Hildrun Haibel³, Maryna Verba⁴, Joachim Sieper³, Jürgen Braun¹, Martin Rudwaleit⁵ and Denis Poddubnyy⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage…
Abstract Number: 1257 • ACR Convergence 2021
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, Zhanguo Li⁹, Yuan An⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Sargunan Sockalingam¹¹, Yanjie Hao¹², Zhuoli Zhang¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Shereen Oon¹⁴, Madelynn Chan¹⁵, YI-HSING CHEN¹⁶, Sang-Cheol Bae¹⁷, Sean O’Neill¹⁸, Kathryn Gibson¹⁸, Fiona Goldblatt¹⁹, Jun Kikuchi²⁰, Tsutomu Takeuchi²¹, Kristine (Pek Ling) Ng²², Nicola Tugnet²³, B.M.D.B. Basnayake²⁴, Yoshiya Tanaka²⁵, C.S. Lau²⁶, Mandana Nikpour²⁷, Vera Golder¹ and Eric Morand²⁸, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹University of Malaya, Kuala Lumpur, Malaysia, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁴Melbourne Health, Parkville, Australia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁸Liverpool Hospital, Sydney, Australia, ¹⁹Flinders Medical Centre, Adelaide, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Div. Rheumatology, Keio University, Tokyo, Japan, ²²North Shore Hospital, Auckland, New Zealand, ²³Auckland District Health Board, Auckland, New Zealand, ²⁴Teaching (General) Hospital, Kandy, Sri Lanka, ²⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁶University of Hong Kong, Hong Kong, Hong Kong, ²⁷University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²⁸School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: Laboratory tests are routine in the management of SLE. In clinical trial endpoints, data from laboratory tests contribute to responder status, but this is…
Abstract Number: 0222 • ACR Convergence 2021
Effects of Multi-Joint Osteoarthritis Phenotypes on Self-Reported Physical Function over 3.5 Years: The Johnston County Osteoarthritis Project
Amanda Nelson¹, Carolina Alvarez¹, Liubov Arbeeva¹, Jordan Renner¹, Virginia Kraus², Duncan Lascelles³ and Yvonne Golightly¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Duke University, Durham, NC, ³North Carolina State University, Raleigh, NC
Background/Purpose: To determine the differential effects of several literature-based definitions of multi-joint osteoarthritis (MJOA) on change in self-reported physical function in a community-based cohort.Methods: We…
Abstract Number: 1259 • ACR Convergence 2021
Association of SLE Responder Index (SRI) Attainment and Long-term Clinical Outcomes
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, C.S. Lau⁹, YI-HSING CHEN¹⁰, Sandra Navarra¹¹, Leonid Zamora¹¹, Zhanguo Li¹², Yuan An¹², Sargunan Sockalingam¹³, Yanjie Hao¹⁴, Zhuoli Zhang¹⁴, Madelynn Chan¹⁵, Yasuhiro Katsumata¹⁶, Masayoshi Harigai¹⁶, Shereen Oon¹⁷, Sang-Cheol Bae¹⁸, Sean O’Neill¹⁹, Kathryn Gibson¹⁹, Jun Kikuchi²⁰, B.M.D.B. Basnayake²¹, Tsutomu Takeuchi²², Kristine (Pek Ling) Ng²³, Fiona Goldblatt²⁴, Annie Law²⁵, Nicola Tugnet²⁶, Yoshiya Tanaka²⁷, Sunil Kumar²⁸, Michael Tee²⁹, Jin Yu Tan³⁰, Chetan Karyekar³¹, Mandana Nikpour³², Vera Golder¹ and Eric Morand³³, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹¹University of Santo Tomas Hospital, Manila, Philippines, ¹²People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹³University of Malaya, Kuala Lumpur, Malaysia, ¹⁴Peking University First Hospital, Beijing, China (People's Republic), ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁷Melbourne Health, Parkville, Australia, ¹⁸Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁹Liverpool Hospital, Sydney, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Teaching (General) Hospital, Kandy, Sri Lanka, ²²Div. Rheumatology, Keio University, Tokyo, Japan, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Flinders Medical Centre, Adelaide, Australia, ²⁵Singhealth, Singapore, Singapore, ²⁶Auckland District Health Board, Auckland, New Zealand, ²⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁸Counties Manukau Health, Auckland, New Zealand, ²⁹University of the Philippines, Quezon City, Philippines, ³⁰Janssen Asia Pacific, Singapore, Singapore, ³¹Janssen R&D, Spring House, PA, ³²University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ³³School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: The SLE Responder Index (SRI) is a composite responder definition employed as a clinical trial endpoint in SLE. Despite its widespread adoption, recent discrepant…
Abstract Number: 0245 • ACR Convergence 2021
Long-term Safety and Effectiveness of Abatacept Treatment in Patients with JIA: 5-year Results from the PRCSG/PRINTO JIA Real-World Registry
Hermine Brunner¹, Daniel Lovell², Michael Henrickson¹, Ruy Carrassco³, Kirsten Minden⁴, Lyudmila Grebenkina⁵, James Nocton⁶, Ingrid Louw⁷, Linda Wagner-Weiner⁸, Gabriel Vega Cornejo⁹, Sylvia Kamphuis¹⁰, Vyacheslav Chasnyk¹¹, Heather Walters¹², Simone Appenzeller¹³, Jordi Anton¹⁴, Alyssa Dominique¹⁵, Robert Wong¹⁶, Lixian Dong¹⁵, Tzuyung Douglas Kou¹⁵, Alberto Martini¹⁷ and Nicolino Ruperto¹⁸, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ³Presbyterian Health Services, Albuquerque, NM, ⁴Charite University Hospital Berlin, Berlin, Germany, ⁵Togliatti City Clinical Hospital №5, Togliatti, Russia, ⁶Medical College of Wisconsin, Milwaukee, WI, ⁷Panorama Medical Centre, Cape Town, South Africa, ⁸University of Chicago (Comer Children's), Chicago, IL, ⁹Crea de Guadalajara/Hospital México Americano, Guadalajara, Mexico, ¹⁰Sophia Children’s Hospital, Erasmus University Medical Center, Rotterdam, Netherlands, ¹¹Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ¹²Cohen Children's Hospital, New York, NY, ¹³Hospital das Clínicas da Universidade Estadual de Campinas, Campinas, Brazil, ¹⁴Hospital Sant Joan de Deu, University of Barcelona, Barcelona, Spain, ¹⁵Bristol Myers Squibb, Princeton, NJ, ¹⁶Bristol Myers Squibb, Basking Ridge, NJ, ¹⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ¹⁸IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Abatacept (ABA) is well tolerated and effective in patients with JIA.1 The Pediatric Rheumatology Collaborative Study Group (PRCSG)/ Paediatric Rheumatology INternational Trials Organisation (PRINTO)…
Abstract Number: 1406 • ACR Convergence 2021
Incidence and General Clinical Features of Giant Cell Arteritis in the ARTESER Multicenter Study
Jesús T. Sánchez-Costa¹, Rafael B. Melero-González², Elisa Fernández-Fernández³, María T. Silva-Diaz⁴, Joaquín M. Belzunegui⁵, Clara Moriano⁶, Julio Sánchez⁷, Judit Lluch⁸, Itziar Calvo⁹, Vicente Aldasoro¹⁰, Lydia Abasolo¹¹, Javier Loricera¹², Alberto Ruíz-Román¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, María J. Garcia-Villanueva¹⁶, Vanessa A. Navarro-Angeles¹⁷, Carles Galisteo¹⁸, Anne Riveros-Frutos¹⁹, Jose A. Román-Ivorra²⁰, Selene Labrada-Arrabal²¹, Margarida Vasques-Rocha²², Carlota L. Iñiguez-Ubiaga²³, María García-González²⁴, Clara Molina-Almela²⁵, María Alcalde-Villar²⁶, Antonio Juan Mas²⁷, Eugenio De Miguel²⁸, Javier Narvaez²⁹, Miguel Ángel gonzalez-Gay³⁰, Noemí Garrido-Puñal¹³, Paula V. Estrada-Alarcon¹⁷ and Ricardo Blanco³¹, ¹Research unit, Spanish Society of Rheumatology, Madrid, Spain, ²Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ³Rheumatology department, La Paz University Hospital, Madrid, Spain, ⁴Complejo Hospitalario Universitario de La Coruña, Coruña, Spain, ⁵Hospital Universitario Donostia, Donostia-San Sebasti, Spain, ⁶Hospital Universitario de León, León, Spain, ⁷Hospital Universitario 12 de Octubre, Madrid, Spain, ⁸Hospital Universitari Bellvitge, Hospitalet de Llobregat, Spain, ⁹Basurto University Hospital, Bilbao, Spain, ¹⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ¹¹Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹³Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital Sant Pau, Barcelona, Spain, ¹⁶Rheumatology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁷Hospital de Sant Joan Despí Moisès Broggi. Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitari Parc Tauli, Saadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²¹Hospital del Mar, Barcelona, Spain, ²²Hospital Universitario Araba, Vitoria-Gasteiz, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, La Laguna, Spain, ²⁵Rheumatology Department, Consorci Hospital General Universitari de Valencia, Valencia, Spain, ²⁶Hospital Universitario Severo Ochoa, Leganés, Spain, ²⁷Rheumatology Department, Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ²⁸Hospital Universitario La Paz, Madrid, Spain, ²⁹Division of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³⁰Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ³¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Epidemiological information on Giant Cell Arteritis (GCA) comes mainly from the Scandinavian countries of northern Europe, which show a higher incidence than the countries…
Abstract Number: 0343 • ACR Convergence 2021
Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
Christine Bacha¹, Anne Dennos², Andrea Knight³, Laura Schanberg⁴, Mary Beth Son⁵, Emily von Scheven⁶, Shahla Amin⁷, Charles Helmick⁸ and Aimee Hersh⁹, ¹Nationwide Children's Hospital, Grandview Heights, OH, ²Duke University, Durham, NC, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Boston Children's Hospital, Brookline, MA, ⁶University of California San Francisco, San Francisco, CA, ⁷CARRA, Durham, NC, ⁸Centers for Disease Control and Prevention, Atlanta, GA, ⁹University of Utah, Salt Lake City, UT
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multi-center, observational registry that collects demographic, clinical, and provider- and patient-reported data from…

« Previous Page
1
…
5
6
7
8
9
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].